Ombitasvir: A potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection

Expert Review of Anti-Infective Therapy

Volumn 12, Issue 9, 2014, Pages 1033-1043

  Gentile, Ivan ^a   Buonomo, Antonio Riccardo ^a   Borgia, Guglielmo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

ABT 450; dasabuvir; interferon free; NS5A; ombitasvir; pegylated interferon; resistance; ribavirin

Indexed keywords

ABT 450; DASABUVIR; OMBITASVIR; PEGINTERFERON; PLACEBO; RIBAVIRIN; ABT-267; ANILIDE; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRUS PROTEIN; VIRUS RNA;

ANEMIA; ANTIVIRAL RESISTANCE; AREA UNDER THE CURVE; ASTHENIA; CLINICAL EFFECTIVENESS; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VIVO STUDY; INSOMNIA; LIVER CIRRHOSIS; MONOTHERAPY; NAUSEA; NONHUMAN; PRURITUS; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VIRAL CLEARANCE; VIRUS LOAD; VIRUS REPLICATION; VOMITING; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL (TOPIC); DRUG COMBINATION; DRUG EFFECTS; DRUG SCREENING; GENETICS; HEPACIVIRUS; METABOLISM; VIROLOGY;

ANILIDES; ANIMALS; ANTIVIRAL AGENTS; CARBAMATES; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HUMANS; RNA, VIRAL; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84905868341     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2014.940898     Document Type: Review

References (90)

1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17(2):107-15
2. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997; 26(3 Suppl 1):15S-20S
3. Sagnelli E, Pisaturo M, Stanzione M, et al. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C. Clin Gastroenterol Hepatol 2013;11(9): 1174-80
4. Coppola N, Gentile I, Pasquale G, et al. Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C. Ann Hepatol 2014;13(1):20-6
5. Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012; 26(4):401-12
6. Gentile I, Coppola N, Pasquale G, et al. A simple noninvasive score based on routine parameters can predict liver cirrhosis in patients with chronic Hepatitis C. Hepat Mon 2013;13(5):e8352
7. Fortunato G, Calcagno G, Bresciamorra V, et al. Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes. J Interferon Cytokine Res 2008;28(3):141-52
8. Fortunato G, Castaldo G, Oriani G, et al. Multivariate discriminant function based on six biochemical markers in blood can predict the cirrhotic evolution of chronic hepatitis. Clin Chem 2001;47(9):1696-700
9. Gentile I, Meola M, Buonomo AR, et al. Human platelet antigen-3 genotype predicts platelet count in patients with HCV infection. In Vivo 2013;27(6):773-7
10. Filippini P, Coppola N, Scolastico C, et al. Does HIV infection favor the sexual transmission of hepatitis C? Sex Transm Dis 2001;28(12):725-9
11. Sagnelli E, Pasquale G, Coppola N, et al. Influence of chronic coinfection with hepatitis B and C virus on liver histology. Infection 2004;32(3):144-8
12. Gentile I, Buonomo AR, Zappulo E, Borgia G. Is it possible to predict HCV-related liver cirrhosis non-invasively through routine laboratory parameters? Infez Med 2014;22(1):11-18
13. Ferrari SM, Fallahi P, Mancusi C, et al. HCV-related autoimmune disorders in HCV chronic infection. Clin Ter 2013; 164(4):e305-12
14. Coppola N, Pisaturo M, Guastafierro S, et al. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Dig Liver Dis 2012;44(1): 49-54
15. Zampino RCN, Cirillo G, Boemio A, et al. Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C. J Viral Hepat 2013;20:517-23
16. Coppola N, Pascalis SD, Pisaturo M, et al. Sustained virological response to antiviral treatment in chronic hepatitis C patients may be predictable by HCV-RNA clearance in peripheral blood mononuclear cells. J Clin Virol 2013;58(4):748-50
17. Fusco F, D'Anzeo G, Rossi A, et al. Erectile dysfunction in patients with chronic viral hepatitis: A systematic review of the literature. Expert Opin Pharmacother 2013; 14(18):2533-44
18. Sagnelli E, Stroffolini T, Mele A, et al. The importance of HCV on the burden of chronic liver disease in Italy: A multicenter prevalence study of 9,997 cases. J Med Virol 2005;75(4):522-7
19. Petruzziello A, Coppola N, Diodato AM, et al. Age and gender distribution of hepatitis C virus genotypes in the metropolitan area of Naples. Intervirology 2013;56(3):206-12
20. Guadagnino V, Stroffolini T, Caroleo B, et al. Hepatitis C virus infection in an endemic area of Southern Italy 14 years later: evidence for a vanishing infection. Dig Liver Dis 2013;45(5):403-7
21. Guadagnino V, Stroffolini T, Rapicetta M, et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: A community-based survey in southern Italy. Hepatology 1997; 26(4):1006-11
22. Gentile I, Di Flumeri G, Scarica S, et al. Acute hepatitis C in patients undergoing hemodialysis: experience with high-dose interferon therapy. Minerva Urol Nefrol 2013;65(1):83-4
23. Carney K, Dhalla S, Aytaman A, et al. Association of tattooing and hepatitis C virus infection: A multicenter case-control study. Hepatology 2013;57(6):2117-23
24. Coppola N, Pisapia R, Tonziello G, et al. Improvement in the aetiological diagnosis of acute hepatitis C: A diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity Index. J Clin Virol 2009;46(3): 222-9
25. Coppola N, Pisapia R, Marrocco C, et al. Anti-HCV IgG avidity index in acute hepatitis C. J Clin Virol 2007;40(2):110-15
26. Gentile I, De Stefano A, Di Flumeri G, et al. Concomitant interferon-alpha and chemotherapy in hepatitis C and colorectal cancer: A case report. In Vivo 2013;27(4): 527-9
27. Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138(2):513-21
28. Gentile I, Viola C, Graf M, et al. A simple noninvasive score predicts gastroesophageal varices in patients with chronic viral hepatitis. J Clin Gastroenterol 2009;43(1): 81-7
29. Gentile I, Borgia G. Surrogate endpoints and non-inferiority trials in chronic viral hepatitis. J Hepatol 2010;52(5):778
30. Braks RE, Ganne-Carrie N, Fontaine H, et al. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol 2007;13(42):5648-53
31. Tsuda N, Yuki N, Mochizuki K, et al. Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. J Med Virol 2004;74(3): 406-13
32. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study. Hepatology 2007; 45(3):579-87
33. Di Marco V, Almasio PL, Ferraro D, et al. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: A randomized controlled trial. J Hepatol 2007;47(4):484-91
34. Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002;347(2): 89-94
35. Takahashi K, Nishida N, Kawabata H, et al. Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection. Intern Med 2012;51(19): 2745-7
36. Morisco F, Granata R, Stroffolini T, et al. Sustained virological response: A milestone in the treatment of chronic hepatitis C. World J Gastroenterol 2013;19(18):2793-8
37. Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013;144(7):1450-5
38. Venkatraman S, Bogen SL, Arasappan A, et al. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2 (S)-[[[(1,1-dimethylethyl)amino]carbonyl] amino]-3,3-dimethyl-1-oxobutyl]-6,6- dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: A potential therapeutic agent for the treatment of hepatitis C infection. J Med Chem 2006; 49(20)):6074-86
39. Tong X, Chase R, Skelton A, et al. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006;70(2):28-38
40. Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets 2006;6(1):3-16
41. Gentile I, Viola C, Borgia F, et al. Telaprevir: A promising protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem 2009;16(9): 1115-21
42. Coppola N, Pisaturo M, Tonziello G, et al. Efficacy of Pegylated interferon alpha-2a and alpha-2b in patients with genotype 1 chronic hepatitis C: A meta-analysis. BMC Infect Dis 2012;12: 357-1471-2334
43. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49(4):1335-74
44. European Medicines Agency recommends approval of sofosbuvir for the treatment of chronic hepatitis C. Agency EM. 2013. Available at www.ema.europa.eu/docs/en/GB/document/library/Press/release/2013/11/WC500155469. pdf [Last accessed 01.02.2014
45. Approval of Sovaldi (sofosbuvir) tablets for the treatment of chronic hepatitis C. FDA. FDA press release; 2013. Available at www.fda.gov/ forconsumers/byaudience/forpatientadvocates/ucm377920.htm; Last accessed 17/01/2014
46. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368(20):1867-77 ABT-267 for treatment of hepatitis C Drug Profile informahealthcare.com 1041
47. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368(20):1878-87
48. Gentile I, Borgia F, Zappulo E, et al. Efficacy and safety of sofosbuvir in treatment of chronic hepatitis C: the dawn of a new era. Rev Recent Clin Trials 2014; 9(1):1-7
49. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir + Ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial. Hepatology 2013;58(4): 733-4
50. Lange CM, Bojunga J, Ramos-Lopez E, et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol 2011;54(5):887-93
51. Ismail MH. Prediction of sustained virologic responses to combination therapy of pegylated interferon-alpha and ribavirin in patients with chronic hepatitis C infection. J Family Community Med 2013;20(1): 35-40
52. Borgia G, Gentile I, Fortunato G, et al. Homocysteine levels and sustained virological response to pegylated-interferon alpha2b plus ribavirin therapy for chronic hepatitis C: A prospective study. Liver Int 2009;29(2):248-52
53. Distante S, Bjoro K, Hellum KB, et al. Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver 2002;22(3):269-75
54. Gentile I, Viola C, Paesano L, et al. Iron depletion before HCV antiviral therapy: A pilot, randomized, controlled trial. J Clin Apher 2009;24(5):190-6
55. Abu-Mouch S, Fireman Z, Jarchovsky J, et al. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients. World J Gastroenterol 2011;17(47):5184-90
56. Nimer A, Mouch A. Vitamin D improves viral response in hepatitis C genotype 2-3 naive patients. World J Gastroenterol 2012;18(8):800-5
57. Coppola N, Marrone A, Pisaturo M, et al. Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection. Eur J Clin Microbiol Infect Dis 2014;33(4):559-67
58. Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54(4):1433-44
59. Gentile I, Borgia F, Buonomo AR, et al. A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir. Curr Med Chem 2013;20(30):3733-42
60. Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56(1):S88-S100
61. Gentile I, Borgia F, Coppola N, et al. Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A. Curr Med Chem 2014;21(12):1391-404
62. Lange CM, Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 2013;58(3): 583-92
63. Gentile I, Buonomo AR, Borgia F, et al. Ledipasvir: A novel synthetic antiviral for the treatment of HCV Infection. Expert Opin Investig Drugs 2014;23(4):561-71
64. Gentile I, Coppola N, Buonomo AR, et al. Investigational NS polymerase inhibitors and their use in treating HCV. Expert Opin Investig Drugs 2014.[Epub ahead of print]
65. Gentile I, Buonomo AR, Borgia F, et al. MK-5172 : A second-generation protease inhibitor for the treatment of hepatitis C virus infection. Expert Opin Investig Drugs 2014;23(5):719-28
66. Gentile I, Zappulo E, Buonomo AR, Borgia G. Interferon-free therapies for chronic hepatitis C: towards an HCV-free world? Expert Rev Anti Infect Ther 2014; 12(7):763-73
67. Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C. Virus into 7 genotypes and 67 Subtypes: updated criteria and assignment web resource. Hepatology 2013;1(10):318-27
68. Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature 2005;436(7053):933-8
69. Parfieniuk A, Jaroszewicz J, Flisiak R. Specifically targeted antiviral therapy for hepatitis C virus. World J Gastroenterol 2007;13(43):5673-81
70. Gentile I, Carleo MA, Borgia F, et al. The efficacy and safety of telaprevir-A new protease inhibitor against hepatitis C virus. Expert Opin Investig Drugs 2010;19(1): 151-9
71. Gao M. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr Opin Virol 2013;3(5):514-20
72. Tellinghuisen TL, Marcotrigiano J, Rice CM. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 2005; 435(7040):374-9
73. Tripathi LP, Kambara H, Chen YA, et al. Understanding the biological context of NS5A-host interactions in HCV infection: A network-based approach. J Proteome Res 2013;12(6):2537-51
74. Qiu D, Lemm JA, O'Boyle DR 2nd, et al. The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization. J Gen Virol 2011;92(Pt 11):2502-11
75. Degoey DA, Randolph JT, Liu D, et al. Discovery of ABT-267, a Pan-Genotypic Inhibitor of HCV NS5A. J Med Chem 2014;15:15
76. Pilot-Matias T, Koev G, Krishnan P, et al. In vitro combinatory effect of HCV NS3/4A Protease Inhibitor ABT-450, NS5A Inhibitor ABT-267, and non-nucleoside NS5B Polymerase Inhibitor ABT-333. In 47th Annual Meeting of the European Association for the Study of the Liver, Barcelona, Spain, 2012
77. Dumas EO, Lawal A, Menon RM, et al. Pharmacokinetics, safety and tolerability of the HCV NS5A Inhibitor ABT-267 following single and multiple doses in healthy adult volunteers. J Hepatol 2011;54:S475-S6
78. Lawitz E, Marbury T, Campbell A, et al. Safety and antiviral activity of ABT-267, a novel NS5A inhibitor, during 3-day monotherapy: first study in HCV genotype-1 (GT1)-infected treatment-naive subjects. J Hepatol 2012;56:S469-S70
79. Khatri A, Gaultier IA, Menon R, et al. Pharmacokinetics and safety of co-administered ABT-450 plus ritonavir (ABT-450/r), ABT-267 and ABT-333 as a single dose in subjects with normal hepatic function and in subjects with mild, moderate and severe hepatic impairment. Hepatology 2012;56:555A-6A
80. Sullivan GJ, Rodriques-Torres M, Lawitz E, et al. ABT-267 combined with Pegylated Interferon alpha-2a/ribavirin in genotype 1 (GT1) HCV-infected treatment-naive subjects: 12 week antiviral and safety analysis. EASL 47th Annual Meeting, Barcelona, Spain; 18-22 April 2012
81. Epstein M, Felizarta F, Marbury T, et al. Study of ABT-267 2-day monotherapy followed by 12-week combination therapy in treatment-naive patients with chronic HCV genotype 1 Infection. J Hepatol 2013;58:S484
82. Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014;370(3):222-32
83. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/rombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370(17):1594-603
84. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/rombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370(17):1604-14
85. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-Ombitasvir and dasabuvir with ribavirin for hepatitis c with cirrhosis. N Engl J Med 2014;11:11
86. Baran RW, Xie W, Liu Y, et al. Health-related quality of life (hrqol), health state, function and wellbeing of chronic hcv patients treated with interferon-free, oral daa regimens: patient reported outcome (PRO) results from the AVIATOR study. Hepatology 2013;58:750A-1A
87. Krishnan P, Beyer J, Koev G, et al. Antiviral activity and resistance profiles for ABT-267, a Novel HCV NS5A inhibitor, in vitro and during 3-day monotherapy in hcv genotype-1 (gt1)-infected treatment-naive subjects. Hepatology 2012;56:1069A
88. Borgia G, Carleo MA, Gaeta GB, Gentile I. Hepatitis B in pregnancy. World J Gastroenterol 2012;18(34):4677-83
89. Gentile I, Zappulo E, Buonomo AR, Borgia G. Prevention of mother-to-child transmission of hepatitis B virus and hepatitis C virus. Expert Rev Anti Infect Ther 2014;20:1-8
90. Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012;61(RR-4):1-32